Workflow
汤臣倍健二季度净利润同比增速回正,新品连发带动品类增长

Core Insights - The company reported a revenue of 3.532 billion yuan and a net profit of 737 million yuan for the first half of 2025, showing signs of recovery in the second quarter with a narrowing revenue decline and a positive net profit growth rate [1][5]. Group 1: Financial Performance - In the first half of 2025, the company achieved a revenue of 35.32 billion yuan and a net profit of 7.37 billion yuan [1]. - The second quarter saw a reduction in revenue decline year-on-year, and net profit growth returned to positive territory [1]. Group 2: Market Challenges and Strategies - The dietary supplement sales in pharmacies experienced a year-on-year decline of approximately 25% from January to May 2025 [3]. - To address challenges such as reduced foot traffic in pharmacies and increased online competition, the company focused on consumer-centric strategies, emphasizing high-quality and cost-effective products [3]. Group 3: Product Innovation and Market Position - The company launched several new products that contributed to market share recovery, including the calcium DK product, which showed significant new customer acquisition [3]. - Online sales of key products like the liquid calcium and multi-layer tablets performed well, with the latter achieving over 10 million yuan in sales within 45 days of launch [4]. - The company is actively pursuing research and development in areas such as anti-aging and precision nutrition, with recent publications in prestigious journals highlighting its scientific advancements [4]. Group 4: Future Outlook - Analysts predict that starting from the second quarter of 2025, the company will experience reduced baseline pressure, with performance expected to improve due to demand recovery, new product launches, and operational efficiency [5]. - The company is also accelerating its expansion into overseas markets, aiming to create additional health value for consumers [5].